[go: up one dir, main page]

Harenberg et al., 1985 - Google Patents

Inhibition of low molecular weight heparin by protamine chloride in vivo

Harenberg et al., 1985

View PDF
Document ID
5771354366457297699
Author
Harenberg J
Gnasso A
De Vries J
Zimmermann R
Augustin J
Publication year
Publication venue
Thrombosis research

External Links

Snippet

To determine the antagonization of anticoagulant and lipolytic effects of a low molecular weight (LMW) heparin preparation protamine chloride was given intravenosly after iv injection of LMW or normal heparin. The effects of normal heparin on factor Xa, thrombin …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof

Similar Documents

Publication Publication Date Title
Harenberg et al. Inhibition of low molecular weight heparin by protamine chloride in vivo
Castellot Jr et al. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells
Holmer et al. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits
Thomas et al. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis
Pejler et al. Structure and antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides.
Holmer et al. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties
Barrowcliffe et al. Anticoagulant activities of lung and mucous heparins
Linhardt et al. Dermatan sulfate as a potential therapeutic agent
Ofosu et al. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate
Barrowcliffe et al. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides
WO1992017187A1 (en) New non-anticoagulant heparin derivatives
JP2003512807A (en) Dermatan disulfate, an inhibitor of thrombin generation and complement activation
Wall et al. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides
RU2153506C2 (en) Dermatan sulfate or its salt, antithrombotic agents, method of prophylaxis and treatment of thrombosis, method of prophylaxis or treatment of disseminated intravascular coagulation syndrome, method of myocardium infarction treatment
Thomas et al. In vivo release of anti-Xa clotting activity by a heparin analogue
Ofosu et al. Heparin with low affinity to antithrombin III inhibits the activation of prothrombin in normal plasma
Harenberg et al. Anticoagulant and lipolytic effects of a low molecular weight heparin fraction
WO1988001280A1 (en) Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
Doutremépuich et al. In vivo neutralization of low-molecular weight heparin fraction CY 216 by protamine
Østergaard et al. The effect of low molecular weight heparin on experimental thrombosis and haemostasis-the influence of production method
Merton et al. High and low affinity heparin compared with unfractionated heparin as antithrombotic drugs
Thomas et al. Low molecular weight heparin: a better drug?
Schwartz Heparin: what is it? How does it work?
Verstraete Heparin and thrombosis: a seventy year long story
Dryjski et al. Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.